ReviewMalaria journal2026
CYP3A and CYP2D6 variability in antimalarial pharmacokinetics and pharmacogenetics across populations: a narrative review.
Review in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria remains a global health burden, requiring optimised antimalarial therapies. This review examines the role of CYP450 3A family and 2D6 alleles in antimalarial drug metabolism, highlighting pharmacogenetics and distribution across populations. A narrative literature review was conducted using a structured literature search of PubMed, Web of Science, and Google Scholar to evaluate how CYP3A and CYP2D6 alleles affect the metabolism of quinine, artemether-lumefantrine, primaquine and tafenoquine. The review analysed genetic variations and interactions with other drugs. CYP3A alleles influence quinine metabolism, with normally functioning alleles (CYP3A4*1 or CYP3A5*1) associated with higher metabolism rates, while decreased- or non-functional alleles (CYP3A4*1B or CYP3A5*3, *6, *7) are associated with reduced metabolism. The impact of CYP3A alleles on artemether-lumefantrine metabolism is less clear but may be relevant in pregnancy, individuals with HIV receiving efavirenz, and individuals with tuberculosis receiving rifampicin. CYP2D6 alleles associated with poor or intermediate metaboliser phenotypes may contribute to primaquine treatment failure, while interactions with drugs like chloroquine or dihydroartemisinin-piperaquine may elevate primaquine plasma concentrations. Tafenoquine could represent a potential alternative in individuals with reduced CYP2D6 activity, as current human studies have not shown an increased relapse risk, although clinical evidence remains limited. Understanding these genetic differences could help explain variability in antimalarial drug exposure and treatment response across diverse malaria-endemic populations. Genotyping may help explain variability in drug exposure or treatment response in selected clinical settings. Pharmacogenetic insights may therefore support safer and more effective antimalarial therapies worldwide.
Indexed as
Identifiers
42888416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.